1. Heterotypic interactions drive antibody synergy against a malaria vaccine candidate
- Author
-
Robert J, Ragotte, David, Pulido, Amelia M, Lias, Doris, Quinkert, Daniel G W, Alanine, Abhishek, Jamwal, Hannah, Davies, Adéla, Nacer, Edward D, Lowe, Geoffrey W, Grime, Joseph J, Illingworth, Robert F, Donat, Elspeth F, Garman, Paul W, Bowyer, Matthew K, Higgins, and Simon J, Draper
- Subjects
Plasmodium falciparum ,Protozoan Proteins ,Antibodies, Monoclonal ,Antibodies, Protozoan ,Antigens, Protozoan ,Cell Line ,Epitopes ,Drosophila melanogaster ,Immunogenicity, Vaccine ,Malaria Vaccines ,Vaccine Development ,Animals ,Humans ,Malaria, Falciparum - Abstract
Understanding mechanisms of antibody synergy is important for vaccine design and antibody cocktail development. Examples of synergy between antibodies are well-documented, but the mechanisms underlying these relationships often remain poorly understood. The leading blood-stage malaria vaccine candidate, CyRPA, is essential for invasion of Plasmodium falciparum into human erythrocytes. Here we present a panel of anti-CyRPA monoclonal antibodies that strongly inhibit parasite growth in in vitro assays. Structural studies show that growth-inhibitory antibodies bind epitopes on a single face of CyRPA. We also show that pairs of non-competing inhibitory antibodies have strongly synergistic growth-inhibitory activity. These antibodies bind to neighbouring epitopes on CyRPA and form lateral, heterotypic interactions which slow antibody dissociation. We predict that such heterotypic interactions will be a feature of many immune responses. Immunogens which elicit such synergistic antibody mixtures could increase the potency of vaccine-elicited responses to provide robust and long-lived immunity against challenging disease targets.
- Published
- 2021